Procedures | Screening | Baseline* | Administration of trial medication | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Time from start of trial drug administration (min) | Follow-up (h) | |||||||||||
15 | 30 | 60 | 120 | 4 | 8 | 12 | 16 | 20 | 24 | |||
Eligibility assessment | X | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Demographics | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Informed consent | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
ECG | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Potassium measurement (K+) | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Randomisation | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Respiratory rate  Oxygen saturations  Blood pressure  Heart rate |  | X | X | X | X | X |  |  |  |  |  |  |
VAS pain score | Â | X | X | X | X | X | X | X | X | X | X | X |
McGill Questionnaire | Â | X | X | X | X | X | Â | Â | Â | Â | Â | Â |
Adverse event assessments | Â | Â | X | X | X | X | X | X | X | X | X | X |
Satisfaction Questionnaire+ | Â | Â | Â | Â | Â | X | Â | Â | Â | Â | Â | Â |
OPTIMISED SWAT Questionnaire+ | Â | Â | Â | Â | Â | X | Â | Â | Â | Â | Â | Â |
Protocol non-compliances | X | X | X | X | X | X | X | X | X | X | X | X |